Effective February 13, 2023, Empagliflozin (Jardiance^®), Glipizide/Metformin, Glyburide (Glynase^®, PresTab^®, DiaBeta^®), and Glimepiride (Amaryl^®) have been added to the ADAP formulary.

Type 2 diabetes mellitus is a common chronic medical condition in adults and people with HIV are at a higher risk for developing diabetes. The American Diabetes Association's 2022 Standards of Medical Care in Diabetes contains a number of updated recommendations for diabetes treatment. The SGLT2 Inhibitor class of diabetes treatment is now one of the preferred medications for many patients, especially for patients with atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease (grade A recommendation).

The addition of an SGLT2 Inhibitor (Empagliflozin) will help modernize the ADAP formulary's options for diabetes treatment. In addition, several second-line medications are being added to the ADAP formulary to provide additional treatment options including Glipizide/Metformin, Glyburide, and Glimepiride.

ADAP management requests that you share this information with your clinical leadership team and local prescribers. The ADAP drug formulary has been updated to reflect the addition of Empagliflozin (Jardiance^®), Glipizide/Metformin, Glyburide (Glynase^®, PresTab^®, DiaBeta^®), and Glimepiride (Amaryl^®)

If you have any questions regarding the addition of these medications to the ADAP formulary, please contact the OA Formulary Specialist, James Vo (James.Vo@cdph.ca.gov ).

Thank you,

​

Sharisse Kemp, MSW

ADAP Branch Chief

California Department of Public Health